Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
275,000,000
-
Total 13F shares
-
264,455,712
-
Share change
-
+6,900,106
-
Total reported value
-
$864,768,038
-
Put/Call ratio
-
53%
-
Price per share
-
$3.27
-
Number of holders
-
152
-
Value change
-
+$29,349,082
-
Number of buys
-
86
-
Number of sells
-
54
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) as of Q3 2025
As of 30 Sep 2025,
Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) was held by
152 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
264,455,712 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, RA CAPITAL MANAGEMENT, L.P., Avoro Capital Advisors LLC, MORGAN STANLEY, BlackRock, Inc., FMR LLC, GOLDMAN SACHS GROUP INC, VANGUARD GROUP INC, Siren, L.L.C., and Octagon Capital Advisors LP.
This page lists
152
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.